NLSPW (NewcelX) 3-1 Month Momentum %: N/A% (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NewcelX 3-1 Month Momentum %?

NewcelX NLSPW 33 3-1 Month Momentum % is N/A% as of Sep. 09, 2026. GuruFocus rates NLSPW with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,386 Biotechnology companies, NewcelX ranks better than 51.88% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), NewcelX's 3-1 Month Momentum % is N/A%.

The industry rank for NewcelX's 3-1 Month Momentum % or its related term are showing as below:

NLSPW's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: 1.085
* Ranked among companies with meaningful 3-1 Month Momentum % only.

NewcelX  (NAS:NLSPW) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

NewcelX 3-1 Month Momentum % Related Terms

NewcelX  (NAS:NLSPW) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
NewcelX (NLSPW) has a 3-1 Month Momentum % of N/A% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on NewcelX and its competitors. According to the industry distribution chart, NewcelX ranks #667 out of 1386 companies in the Biotechnology industry, placing it in the top 48.1%.
Is NewcelX's 3-1 Month Momentum % too high?
NewcelX's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, NewcelX ranks #667 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NewcelX has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NewcelX's 3-1 Month Momentum % compare to BIVI and PTN?
According to the Biotechnology industry distribution chart, NewcelX ranks #667 out of 1386 companies for 3-1 Month Momentum %. This puts NewcelX in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.09, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on NewcelX and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewcelX's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewcelX stock overvalued right now?
NewcelX (NLSPW) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. NewcelX's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For NewcelX (NLSPW), the current 3-1 Month Momentum % is N/A% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NewcelX Business Description

Other Exchanges NCEL:USA
Address Hohstrasse 1, Kloten, CHE, 8302
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.